Dr. Mittendorf Highlights FDA Approval of Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center, discusses the approval of atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) in patients with locally advanced or metastatic PD-L1–positive triple-negative breast cancer.